Designs and develops personalised medicines



New media



Deal type

Growth Capital

Investment size

Undisclosed - 15.7x return

Investment date(s)

2004 - 2009

The business

  • A designer and developer of personalised medicines
  • Supplies the pharmaceutical industry with crucial biomarkers and companion diagnostics for use in the development of cancer fighting drugs
  • A management buy out from pharmaceutical giant, AstraZeneca

The strategy

  • Grow market share rapidly via strategic partnerships
  • Widen the offering of products and services for use in clinical drug testing
  • Continue innovation by investing in new product pipeline and via commercial partnerships

The developments

  • Successfully developed and brought to market the world’s first companion diagnostic
  • Increased the value of the business by 11x in the first five years since initial investment
  • Sold to Qiagen generating a 15.7x return for YFM funds
Back to top